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Abstract
Background: Levetiracetam can be used for seizure control alone or in combination with other antiepileptic
medications. A previous study achieved the minimum targeted serum drug concentration after rectal administration
of levetiracetam in healthy dogs. The purpose of the present study was to determine the pharmacokinetics of rectal
LEV in dogs presented for cluster seizures or status epilepticus and potentially in treatment with other anti-epileptic
drugs. Furthermore, preliminary information on response to this treatment as add-on to the standard treatment protocol
is reported.
Results: Eight client-owned dogs were enrolled. Plasma levetiracetam concentrations (measured at 0, 30, 60, 90, 120, 180,
240, 360, 720, and 1440 min after drug administration) reached the minimum target concentration (5 μg/ml) at 30 min in
all but one patient. At T1 (30 min) the mean concentration was 28.2 ± 15.5 μg/ml. Plasma concentrations remained above
the targeted minimum concentration in all patients until 240 min and in 7/8 until 360 min. Six out of eight patients
experienced no seizures in the 24-h period after hospitalization and were classified as “responders”.
Conclusions: Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in
dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs. These
preliminary results may encourage the evaluation of rectal levetiracetam as an additional treatment option for cluster
seizures and status epilepticus in a larger number of dogs.
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Background
Canine epilepsy is among the most common neurological
diseases in dogs [1]. Cluster seizures (CS) are defined as the
occurrence of two or more seizures within a 24-h period,
with complete recovery of the state of consciousness in
between; status epilepticus (SE) refers to seizure activity
lasting for 5 min or longer or when there’s no complete
recovery of the state of consciousness between two seizure
events [2]. CS and SE are potentially life-threatening
neurological emergencies and are considered risk factors
for spontaneous death or euthanasia of dogs affected by
epilepsy [3–7]. As such, these conditions are a frequent rea-
son for presentation to emergency veterinary services [8, 9].
To date, first line therapy is intravenous or rectal adminis-
tration of diazepam during the seizure event [10–12].
Unfortunately, not all dogs will respond to benzodiazepines
and can experience refractory SE. Moreover, prolonged
seizure activity is known to decrease the effectiveness of
benzodiazepines in human medicine [13]. Levetiracetam
(LEV), a pyrrolidone derivative, is a novel antiepileptic drug
that was approved in the United States in 1999 for the oral
treatment of partial onset seizures in humans [14]. Its
mechanism of action is not fully understood, but it seems
to differ completely from other antiepileptic medications
(AEDs). LEV is thought to act by binding the synaptic
vesicle protein 2A on the presynaptic terminal, thus modu-
lating exocytosis of neurotransmitters [15]. Due to its favor-
able therapeutic profile, LEV has been increasingly used for
seizure control either alone or in combination with other
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first line AEDs in veterinary medicine [16]. In their study
published in 2014, Peters and colleagues found a rapid rise
in serum LEV concentrations associated with maintenance
of values above the targeted minimum concentration up to
9 h after rectal administration of a LEV formulation in
healthy dogs [17].
Based on these premises, the aim of this pilot study was
to determine the pharmacokinetics of LEV administered
per rectum in dogs presented for CS or SE and possibly
already in treatment with other long-term AEDs. We
hypothesized that LEV administered per rectum would
achieve the targeted minimum plasma drug concentration
in patients affected by CS and SE. Furthermore, we report
the response to treatment as preliminary information on
the potential association of LEV administered per rectum
as an adjunct to standard treatment in patients referred
for CS and SE.
Methods
Animals
The study was approved by the Bioethics Committee of
the University of Turin (protocol #9834 dated 25/02/
2016). The owners gave their written, informed consent to
their dog’s enrollment in the study. Client-owned dogs
(minimum weight 20 kg) presented with CS or SE to the
Veterinary Teaching Hospital (VTH), Department of
Veterinary Science of Turin, between October 2016 and
April 2017 were eligible for inclusion. SE was defined as a
seizure event lasting more than 5 min or two or more
seizures without complete recovery of consciousness in
between. CS were defined as two or more seizures
occurring within a 24-h period. Dogs were excluded if
they were already in treatment with LEV for long-term
seizure control or if further diagnostic tests indicated
reactive seizures.
Study design
At the time of presentation to the VTH, seizure activity was
immediately controlled by standard care comprising rectal
administration of diazepam (at a dosage of 1–2 mg/kg if
the dog was seizuring at presentation) followed by IV
administration of phenobarbital (4–5 mg/kg q8h). As soon
as possible after hospitalization, and always within 2 h from
the presentation, LEV suspension (at a dosage of 40 mg/kg)
was administered per rectum. The dosage was based on the
results of a previous study [17]. A rigid, sterile, male dog
urinary catheter (BUSTER Disposable Dog Catheter, Buster,
Kruuse, Germany) was cut to 5 cm length and inserted
approximately 3 to 4 cm into the rectum. A syringe was
then connected to inject the drug. The catheter was flushed
with air immediately after the injection to ensure the
administration of the remaining portion of LEV in the
catheter. After removal of the catheter from the rectum,
the anus was held closed for 5 min to prevent drug
expulsion. The procedure was performed by the same
investigator (G.C.) in all patients.
Venous blood samples were obtained immediately
before drug administration (T0), and at 30 (T1), 60 (T2),
90 (T3), 120 (T4), 180 (T5), 240 (T6), 360 (T7), 720 (T8),
and 1440 (T9) min thereafter. Blood samples were
collected in ethylenediaminetetraacetic acid tubes, and
plasma was separated immediately after sampling by
centrifugation at room temperature (3500 × g, 5 min) and
then frozen at − 20 °C until analysis. Patients were
assessed for signs of adverse reactions specifically attribut-
able to LEV administration (decreased appetite and vomit-
ing) by the same investigator (G.C.) at each time point
and between the experimental time points by the intensive
care unit veterinarians.
For the assessment of treatment efficacy, dogs were
defined as “responders” if no further epileptic seizures
occurred during the 24-h observation period between
hospital admission and discharge; “non-responders” were
dogs that experienced an additional epileptic seizure despite
LEV administration in addition to the above-mentioned
protocol in the 24-h period.
Levetiracetam suspension
Pure LEV powder (Levetiracetam European Pharmacopoeia
Reference Standard, Sigma-Aldrich, Saint Louis, MO, USA)
was purchased and mixed with sterile water to make a
suspension with a LEV concentration of 200 mg/ml. This
was done to reduce the volume of solution for rectal
administration and minimize the risk of accidental evacu-
ation of the drug. The suspension was formulated and
replaced every month. LEV suspension was stored at room
temperature away from direct light and always vigorously
shaken to suspend the powder before administration.
Determination of plasma levetiracetam concentrations
Levetiracetam powder and all other reagents were
purchased from Sigma-Aldrich. LEV was analyzed on a
high-performance liquid chromatography (HPLC)
system (Dionex Thermo Fischer Scientific, Sunnyvale,
CA, USA) and separation was performed on a C18,
5 μm, chromatography column (Dionex Thermo Fischer
Scientific) protected by a security guard precolumn.
Chromatographic run was carried out at 35 °C for
20 min with a step gradient starting at 0 min with 95%
solvent A (H3PO4 0.423% in water) and reaching 100%
solvent B (acetonitrile) at 12 min. Detection was
performed at λ = 210 nm. The limit of detection was
1 μg /ml. For LEV extraction, 500 μl of plasma were
mixed with 10 μl of HClO4 and 500 μl of methanol. The
samples were then vortexed for 2 min and centrifuged at
17,000 × g for 5 min. Forty microliters of supernatant
were then analyzed by HPLC. The unknown concentra-
tions of LEV in samples were quantified by comparing
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the signal to standard calibration curve (R2 = 0.9947).
The recovery percentage was 99.2 ± 4.9%.
Data analysis
Continuous variables, including patient age and weight at
inclusion, were reported as median (minimum – max-
imum) [min – max]. Pharmacokinetic parameters were
estimated by plotting LEV concentrations versus time.
Data were analyzed using a Chromelion 6 Chromatog-
raphy data system (Chromelion 6 Chromatography data
system, Thermo Fischer Scientific), and statistical analysis
was performed using GraphPad InStat 3.0 (GraphPad
InStat 3.0, GraphPad Software, La Jolla CA, USA). Param-
eters were area under the curve (AUC), maximum
concentration (Cmax), time to maximum concentration
(Tmax), and half-life (t ½). Non-compartmental analysis
was performed with AUC calculated using the linear trap-
ezoidal method. The Shapiro-Wilk test showed normal
distribution of the dataset; data were reported as mean ±
standard deviation (SD).
Results
A total of 36 dogs were presented for CS or SE to the
VTH between September 2016 and April 2017. Eight
dogs met the inclusion criteria and were included in the
study. The other 28 patients were excluded because:
body weight less than 20 kg (16/28), no consent given by
the owners for inclusion in the study (7/28), long-term
oral LEV administration for seizure control (3/28), and
diagnosis of reactive seizures (2/28).
Among the eight dogs included in the study, five were
intact females and three were males (two intact and one
neutered); the median age and weight at presentation were
75 months (range, 43–126) and 34 kg (range, 24–52),
respectively. Detailed information on signalment and
history are reported in an additional file (see Add-
itional file 1). Blood work comprising complete
hematology and biochemistry panel, bile acid stimulation
test, and blood ammonia concentration resulted within
normal limits. Four dogs were diagnosed with suspected
idiopathic epilepsy based on signalment, history, and nor-
mal interictal neurological examination. Magnetic reson-
ance imaging (MRI) and cerebrospinal fluid (CSF) analysis
were available for only one patient and were unremark-
able. Signalment, history, and abnormal interictal neuro-
logical examination aroused suspicion of structural
epilepsy in the four other patients. In two of these cases a
neoplastic lesion (suspected glioma) was confirmed by
MRI investigation. A space-occupying lesion was sus-
pected in the other two patients based on signalment and
the findings of neurological examination. The neurological
examination was performed by a board-certified neurolo-
gist (A.D.A.) or a neurology resident (G.C.) under supervi-
sion of the board-certified neurologist.
At the time of inclusion in the study, four out of eight
dogs had been receiving phenobarbital (PB) therapy for
long-term seizure control; two were concurrently receiving
potassium bromide (KBr) and one patient was on treatment
with Imepitoin. The remaining three dogs had not received
any previous AED therapy (see Additional file 1). The
patients receiving PB alone or in combination with KBr
had been in treatment for longer than the period needed to
achieve steady state of the drugs (14 days and 1–3 months,
respectively). PB dosage varied from 2.6 to 6.3 mg/kg q12h,
(median, 3.6 mg/kg q12h); the KBr dosage was 40 and
27 mg/kg q24h in each of the two dogs, respectively. Imepi-
toin was administered at a dosage of 15.7 mg/kg q12h.
Plasma LEV concentrations at the nine time points are
shown in Fig. 1. At the first experimental time point (T1)
the mean concentration was 28.2 ± 15.5 μg/ml (n = 8). At
Fig. 1 Time course of plasma LEV concentration after rectal administration
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this time point (T1), plasma LEV concentrations reached
the minimum target concentration of 5 μg/ml in all but
one patient, in which it was slightly lower than the target
(4.7 μg/ml). Plasma LEV concentrations remained above
the minimum target range in all patients until T6 and in
7/8 (88%) patients at T7.
The plot of plasma LEV concentration versus time
showed a lower peak concentration and a more rapid
decrease in LEV concentration over time in two patients.
Pharmacokinetic analysis of the data from the eight dogs
revealed a Cmax of 36.0 ± 14.4 μg/ml, with a Tmax of 90 ±
60 min. The t ½ was 251.7 ± 75.6 min and the AUC
227.8 ± 131.8 μg-h/ml.
Six out of eight patients (75%) experienced no further
seizures during the 24-h observation period and between
hospital admission and discharge. Two patients (25%), di-
agnosed with confirmed and suspected idiopathic epilepsy,
respectively, and both with lower peak concentrations and
a more rapid decrease in LEV concentration over time,
were classified as “non-responders”. They required further
medications (constant rate infusions of diazepam in one
and constant rate infusion of propofol in the other) for
seizure control.
Considering the different outcomes, a post-hoc analysis
was carried out with the patients grouped into “responders”
(n = 6) and “non-responders” (n = 2). The results are shown
in Table 1.
Discussion
To our knowledge, this is the first study to evaluate LEV
concentration after rectal administration in dogs presenting
with CS or SE and potentially receiving concurrent therapy
with other AEDs for long-term seizure control. In line with
the observations reported by Peters and colleagues [17],
our results show that the targeted minimum plasma LEV
concentration can be achieved with rectal administration of
40 mg/kg. In the majority of cases, plasma concentrations
reached the minimum targeted concentration after rapid
absorption, already at the first blood sample taken 30 min
after administration of the drug. A therapeutic range of
LEV specific for dogs has not yet been established. The
values of 5–45 μg/ml typically employed in veterinary
medicine are deduced from human medicine [18]. The
therapeutic range is highly variable, however, even in hu-
man patients, and mainly in correlation with age [19].
Peters and colleagues highlighted the potential risk of
lower LEV absorption after rectal administration if
palpable fecal material is present in the rectum [17]. The
lower values of Cmax and Tmax for the two dogs in our
series may be associated with less absorption of the drug
due to the presence of fecal material. Another possible
explanation for the different results is the concurrent
long-term administration of PB. Indeed, LEV undergoes
predominant renal excretion as unchanged drug (47 and
58% in female and male dogs, respectively). The
remaining percentage of the drug is metabolized as acid
metabolites and hydroxylated metabolites by hydrolysis
and oxidation, respectively. This latter route of degrad-
ation was found to be induced by PB in rats and dogs
[20]. Further investigations on dogs confirmed that
chronic PB administration alters the metabolism of LEV,
resulting in lower concentrations and more rapid renal
clearance of LEV when administered per os [21, 22]. In
all studies performed in veterinary medicine, only 21 days
of PB administration were proven sufficient to increase
metabolism of LEV, so the chronic PB administration is
an unlikely explanation for the results in these two dogs.
Unfortunately, we did not check for the presence of fecal
material since we wanted to replicate the conditions in
which rectal administration is performed in clinical
settings. While this could be the most plausible explan-
ation, we are unable to determine whether the lower
drug absorption was due to any fecal material potentially
present at the time of administration. This issue repre-
sents a limitation of the present study. Further studies
are needed to evaluate the pharmacokinetics of rectal
LEV in patients concurrently receiving PB, while exclud-
ing the confounding factor of feces present in the
rectum. If this assumption is confirmed, it could also be
interesting to assess the feasibility and safety of higher
doses of LEV administered per rectum in patients under
PB therapy.
One of the two dogs classified as “non-responders”
had been diagnosed with idiopathic epilepsy at the time
of inclusion in the study. According to the revised
definition of pharmacoresistant epilepsy issued by the
International League Against Epilepsy in human medi-
cine in 2010 [23], this patient can be classified as phar-
macoresistant, and so this condition could explain the
patient’s non-responsiveness to treatment. Since seizure
Table 1 Pharmacokinetics parameters
Cmax
(μg/ml)
Tmax
(min)
AUC0-t
(μg-h/ml)
t ½
(min)
“Non-responders”
(n = 2)
12.7 and 17.53 90 and 30 89.63 and 105.24 153 and 249
“Responders”
(n = 6)
43.02 ± 7.27 100.2 ± 64.8 337.94 ± 83.41 268.6 ± 75.8
No adverse effects specifically attributable to LEV administration were noted at any time point
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frequency was not recorded by the owner of the second
non-responder patient diagnosed with suspected idio-
pathic epilepsy, it is impossible to establish whether this
dog can be classified as pharmacoresistant as well. If
LEV efficacy can be demonstrated in a larger number of
cases, achievement of the targeted minimum LEV
plasma concentration with rectal administration in epi-
leptic dogs might allow at-home use of this formulation
for better seizure control. The usage of IV/oral LEV in
so-called “pulse treatment” for cluster seizures is well
known [16, 18]. Nevertheless, in dogs experiencing
seizures, the administration of oral medications may be
delayed by the post-ictal phase, potentially leading to
further seizure events. The rectal route of administration
would avoid this delay and improve seizure control.
In our study, we formulated LEV suspension at a con-
centration of 200 mg/ml to reduce as much as possible
the volume of medication introduced into the rectum,
thus preventing induction of defection and subsequent
accidental expulsion of the drug. The LEV suspension was
made using pure LEV powder for scientific reasons. We
also made LEV suspension from commercially available
LEV tablets and found no differences in the chemical
purity of the two formulations (data available from the
authors on request).
The main limitations of the present study are the small
patient series, the concomitant use of other AEDs, and
the absence of a control group of patients for comparison.
The designation of “responder” and “non-responder” was
in reference to the combination of medications adminis-
tered, and therefore it is not possible to discern any
potential effect of rectal LEV administration. Therefore,
we cannot conclude that rectal LEV is effective in prevent-
ing the onset of further seizures in patients with CS or SE.
Nonetheless, these preliminary pharmacokinetic data are
promising and are consistent with those reported by
Peters and colleagues. Given the postulated enhancement
of the anticonvulsive effects of benzodiazepines and the
lack of side effects, such as cardiac and respiratory depres-
sion typical of other AEDs, [24] LEV can offer a potentially
useful add-on to the treatment of seizure activity in dogs
once its efficacy has been confirmed in a greater number
of cases. Further studies are needed to confirm or confute
our preliminary hypothesis. A future area of focus of this
project is to better evaluate the efficacy of rectal LEV in a
larger number of cases.
Conclusions
In conclusion, our findings show that targeted minimum
plasma LEV concentration can be reached after rectal
administration of 40 mg/kg in dogs with CS or SE. These
preliminary results, if confirmed, may allow for the use of
rectal LEV as an additional treatment option for CS and
SE in dogs.
Additional file
Additional file 1: Signalment and history information of patients
included. Information on signalment, seizure frequency, diagnosis
(if achieved) of patients included in the study. (XLSX 27 kb)
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